

# Talha Badar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7922571/publications.pdf>

Version: 2024-02-01

69  
papers

663  
citations

623734

14  
h-index

677142

22  
g-index

69  
all docs

69  
docs citations

69  
times ranked

1049  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
2	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374.	0.8	48
3	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
4	Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. <i>American Journal of Hematology</i> , 2016, 91, 800-805.	4.1	31
5	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
6	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015, 90, 769-773.	4.1	27
7	Genetic features and clinical outcomes of patients with isolated and comutated <i>DDX41</i> -mutated myeloid neoplasms. <i>Blood Advances</i> , 2022, 6, 528-532.	5.2	27
8	Outcomes of <i>TP53</i> -mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	24
9	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	5.2	21
10	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
11	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020, 4, 47-54.	5.2	20
12	Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 16.	3.0	19
13	Ibrutinib: a paradigm shift in management of CLL. <i>Expert Review of Hematology</i> , 2014, 7, 705-717.	2.2	17
14	Improvement in clinical outcome of <i>FLT3</i> ITD mutated acute myeloid leukemia patients over the last one and a half decade. <i>American Journal of Hematology</i> , 2015, 90, 1065-1070.	4.1	17
15	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. <i>Leukemia and Lymphoma</i> , 2020, 61, 1418-1427.	1.3	16
16	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
17	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	4.1	15
18	Recent advances in understanding and treating immunoglobulin light chain amyloidosis. <i>F1000Research</i> , 2018, 7, 1348.	1.6	14

#	ARTICLE	IF	CITATIONS
19	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	13
20	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
21	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11
22	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	4.1	11
23	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	1.4	10
24	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	10
25	Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 113-120.	2.3	10
26	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. <i>European Journal of Haematology</i> , 2016, 97, 342-347.	2.2	9
27	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. <i>British Journal of Haematology</i> , 2020, 190, e98-e101.	2.5	9
28	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	1.4	9
29	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	2.4	7
30	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 683-685.	2.4	7
31	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	2.2	6
32	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	1.4	5
33	A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma. <i>Blood</i> , 2021, 138, 4401-4401.	1.4	5
34	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. <i>Blood</i> , 2021, 138, 2158-2158.	1.4	5
35	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	1.3	4
36	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Prospect of CAR T-cell therapy in acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2022, 31, 211-220.	4.1	4
38	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. Journal of Clinical Apheresis, 2019, 34, 686-691.	1.3	3
39	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leukemia and Lymphoma, 2019, 60, 940-946.	1.3	3
40	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. European Journal of Haematology, 2021, 107, 301-310.	2.2	3
41	Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2019, 134, 5068-5068.	1.4	3
42	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab. Blood, 2019, 134, 3809-3809.	1.4	3
43	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 210-215.	3.0	2
44	Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. Biology of Blood and Marrow Transplantation, 2020, 26, S101-S102.	2.0	2
45	Do histone deacetylase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. Expert Opinion on Investigational Drugs, 2021, 30, 665-673.	4.1	2
46	Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. Blood, 2021, 138, 797-797.	1.4	2
47	DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. Blood, 2021, 138, 3693-3693.	1.4	2
48	Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen. Leukemia Research Reports, 2022, 17, 100286.	0.4	2
49	A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2022, 40, TPS7070-TPS7070.	1.6	2
50	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin. Blood, 2019, 134, 1302-1302.	1.4	1
51	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 3997-3997.	1.4	1
52	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 3483-3483.	1.4	1
53	Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution experience.. Journal of Clinical Oncology, 2018, 36, e12662-e12662.	1.6	1
54	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	1
56	Clinicopathologic characteristics and treatment outcomes of <i>de novo</i> myeloid sarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19002-e19002.	1.6	1
57	Morbid obesity is related with adverse outcomes in triple negative breast cancer: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12663-e12663.	1.6	0
58	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153.	1.4	0
59	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2918-2918.	1.4	0
60	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	1.4	0
61	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019, 134, 1554-1554.	1.4	0
62	Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20064-e20064.	1.6	0
63	Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies. <i>Blood</i> , 2021, 138, 3688-3688.	1.4	0
64	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). <i>Blood</i> , 2021, 138, 3437-3437.	1.4	0
65	Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE <sup>®</sup> Antibody Blinatumomab (Blinicyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 4404-4404.	1.4	0
66	A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
67	Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in Combination with Bortezomib for Newly Diagnosed Multiple Myeloma Treatment: A Systematic Review. <i>Blood</i> , 2020, 136, 42-42.	1.4	0
68	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19014-e19014.	1.6	0
69	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7080-TPS7080.	1.6	0